An observational study in CLL, sponsored by Peking University People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Peking University People's Hospital · Observational
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
1,780 studies on the registry are indexed under Leukemia, Lymphoid; 176 are open to participants now.
This study's planned enrollment of 490 is above the median of 112 across 227 observational studies indexed under Leukemia, Lymphoid.
Browse Leukemia, Lymphoid studies →Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Investigators participating in this observational study should include all patients with CLL who initiated treatment with zanubrutinib over the period from July 1st, 2020 to the present, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.
Exclusion Criteria:
-
patients with treatment naive or R/R CLL who treatment with Zanubrutinib
Progression Free Survival (PFS)
PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
Time frame: up to two years
Overall Survival
OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause.
Time frame: up to two years
Time to Next Therapy (TTNT)
The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL
Time frame: up to two years
Adverse Events
Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations
Time frame: up to two years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital